Affymax, Takeda recall anaemia drug Omontys after deaths

TOKYO Sat Feb 23, 2013 11:22pm EST

TOKYO Feb 24 (Reuters) - U.S. Affymax Inc. and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anaemia treatment Omontys (peginesatide) in the U.S., due to reports of serious hypersensitivity reactions, including some deaths.

As of Sunday, fatal reactions to the injection have been reported in approximately 0.02 percent of 25,000 patients after receiving their initial injection of the treatment, Affymax said in a statement.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
no deaths have been reported, your headline is severely misleading

needs correction

Feb 24, 2013 3:00am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.